Through the use of measurement, control, information technology and life science, radically improve productivity across the entire value chain, from basic research to logistics and services.
Doted lines indicate Solutions under development.
YOKOGAWA is working on the development of single cell mass spectrometry and single cell gene analysis. In order to analyze one cell with high sensitivity, we are developing a method of collecting target cells while keeping position information under observing cells with confocal scanner.
YOKOGAWA aims to cost reductions and improve safety by providing a structure and data-management platform for unified management of information related to cellular and regenerative therapies.
Yokogawa is contributing to the development of the pharmaceutical industry based on its performance of introducing over 1,000 systems in the areas of drug substances, pharmaceutical products, and biotechnology.
In addition to daily improvement cycles, Yokogawa will use IIoT to support create environments that do not cause defects and that are designed to completely reduce losses.
In August 2017, Yokogawa announced its long-term sustainability goals (Three Goals) for the year 2050. Yokogawa established these goals to contribute to achieving Net-zero emissions, Circular economy and Well-being. In April 2018, Yokogawa strengthened the business structure of its life innovation business with the aim of achieving one of these goals, well-being.
- Low invasiveness enables single-cell injection of target substances and extraction of intracellular materials -
- A system that ensures compliance with industry regulations and decreases risk to improve efficiency -
- Supporting drug development research through the use of HCA and three-dimensional culture models -
- Collaboration to widen use of N-NOSE cancer screening test -
Szukasz dodatkowych informacji na temat naszych pracowników, technologii i rozwiązań?